CanariaBio Inc Announces Enrollment Completion of randomized Phase 2 study of Oregovomab in combination with chemotherapy as neo-adjuvant treatment of patients with Advanced Ovarian Cancer
- Written by PR Newswire
![]() |
SEOUL, South Korea, Aug. 23, 2024 /PRNewswire/ -- CanariaBio Inc, a leading late-stage biotechnology company, announces the successful completion of enrollment of 88 patients in a randomized Phase 2 study of oregovomab in combination with chemotherapy (paclitaxel and carboplatin) as neo-adjuvant treatment of patients with newly diagnosed advanced...















